|
|
|
|
|
||
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
|
Fig. 7. Treatment of skeletal myoblasts with MURF-2 antisense oligonucleotides delays fusion events. Primary cultures of chick myoblasts were treated with control or MURF-2 antisense oligonucleotides and observed by phase microscopy at different stages of differentiation. Within 24 hours of treatment, control myoblasts were elongating, aligning, and beginning to fuse (a, arrows). In contrast, myoblasts treated with MURF-2 antisense oligonucleotides were elongated, but were not fusing (b, arrows). Within 48 hours of treatment, control myotubes were fusing extensively, although MURF-2 antisense-treated cells appeared only to be beginning to fuse (c,d, arrows). Control myotubes were thick and branched within 72 hours of treatment (e, arrow) and were often twitching, although antisense-treated myotubes appeared thinner, much less branched (f, arrow), and were not observed to twitch. Within 96 hours of treatment, control and antisense-treated myotubes appeared indistinguishable by light microscopy (g,h, arrows), and both populations of myotubes were observed to twitch.
|
